ProMIS Neurosciences licenses Ossianix brain-delivery technology for Alzheimer's antibody
PMN•ProMIS Neurosciences licensed Ossianix's TXP1 brain-delivery technology for its PMN310 Alzheimer's antibody, with options to extend it to two other drug candidates. Ossianix is eligible for milestone payments and royalties, while ProMIS said the agreement is not expected to change its projected cash runway through 2027.
1. License terms
ProMIS Neurosciences licensed Ossianix's TXP1 brain-delivery technology for its PMN310 Alzheimer's antibody. The agreement includes options to extend TXP1 to PMN442 for Parkinson's disease and PMN267 for ALS. Ossianix will receive an upfront payment and is eligible for development, regulatory and commercial milestones, plus royalties on global net sales.
2. Preclinical results
Ossianix reported that TXP1 increased antibody delivery to the brain by more than 65-fold in preclinical studies. ProMIS said existing cash will fund short-term obligations and the agreement is not expected to change its projected cash runway through 2027.




